Blood levels of carbonic anhydrase 9 correlate with clear cell renal cell carcinoma activity

Clinical Proteomics

Volumn 5, Issue 1, 2009, Pages 37-45

  Hulick, Peter ^a   Zimmer, Michael ^a   Margulis, Vitaly ^e   Skates, Steven ^a   Hamel, Maureen ^a   Dahl, Douglas M ^a   Michaelson, Dror M ^a   Liebermann, Towia ^b   Signoretti, Sabina ^c   Carney, Walter ^d   Wood, Christopher ^e   Iliopoulos, Othon ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Siemens Diagnostics Inc   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Carbonic anhydrase 9; Circulating biomarker; Hypoxia inducible factor; Renal cell carcinoma; VHL

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX;

ARTICLE; CANCER GROWTH; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY DISEASE; MALE; NEPHRECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 70349572784     PISSN: 15426416     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12014-008-9012-1     Document Type: Article

References (26)

1. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 17237035 10.3322/canjclin.57.1.43
2. O Iliopoulos 2006 Molecular biology of renal cell cancer and the identification of therapeutic targets J Clin Oncol 24 5593 5600 17158545 10.1200/JCO.2006.08.8948 1:CAS:528:DC%2BD2sXmvVSqtw%3D%3D (Pubitemid 46631340)
3. RJ Motzer NH Bander DM Nanus 1996 Renal cell carcinoma N Engl J Med 335 865 875 8778606 10.1056/NEJM199609193351207 1:STN:280:DyaK28zlslajtA%3D%3D (Pubitemid 26304070)
4. J Brugarolas 2007 Renal-cell carcinoma-molecular pathways and therapies N Engl J Med 356 185 187 17215538 10.1056/NEJMe068263 1:CAS:528: DC%2BD2sXksVOjug%3D%3D (Pubitemid 46089681)
5. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
6. RC Kane AT Farrell H Saber, et al. 2006 Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 7271 7278 17189398 10.1158/1078-0432.CCR-06-1249 1:CAS:528:DC%2BD28XhtlCrtr7P (Pubitemid 46095398)
7. R Motzer MD Michaelson BG Redman, et al. 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24 16330672 10.1200/JCO.2005.02.2574 1:CAS:528:DC%2BD28Xot1ChtA%3D%3D (Pubitemid 46630489)
8. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
9. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
10. SY Liao ON Aurelio K Jan J Zavada EJ Stanbridge 1997 Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney Cancer Res 57 2827 2831 9230182 1:CAS:528:DyaK2sXkslOkt74%3D
11. CC Wykoff NJ Beasley PH Watson, et al. 2000 Hypoxia-inducible expression of tumor-associated carbonic anhydrases Cancer Res 60 7075 7083 11156414 1:CAS:528:DC%2BD3MXjsVOhtw%3D%3D
12. MH Bui H Visapaa D Seligson, et al. 2004 Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma J Urol 171 2461 2466 15126876 10.1097/01.ju.0000116444.08690.e2 (Pubitemid 38625515)
13. M Atkins M Regan D McDermott, et al. 2005 Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer Clin Cancer Res 11 3714 3721 15897568 10.1158/1078-0432.CCR-04-2019 1:CAS:528:DC%2BD2MXktFyrt7Y%3D (Pubitemid 40685588)
14. G Li G Feng A Gentil-Perret C Genin J Tostain 2007 CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy Clin Exp Metastasis 24 3 149 155 17390110 10.1007/s10585-007-9064-z (Pubitemid 46850226)
15. J Jones H Otu D Spentzos, et al. 2005 Gene signatures of progression and metastasis in renal cell cancer Clin Cancer Res 11 5730 5739 16115910 10.1158/1078-0432.CCR-04-2225 1:CAS:528:DC%2BD2MXos1Cjsbs%3D (Pubitemid 41170297)
16. O Iliopoulos A Kibel S Gray WG Kaelin 1995 Tumor suppression by the human von Hippel-Lindau gene product Nat Med 1 822 826 7585187 10.1038/nm0895-822 1:CAS:528:DyaK2MXnt1ynu7c%3D
17. M Zimmer D Doucette N Siddiqui O Iliopoulos 2004 Inhibition of hypoxia inducible factor is sufficient for growth suppression of VHL-/- tumors Mol Cancer Res 2 89 95 14985465 1:CAS:528:DC%2BD2cXisVGqtb8%3D
18. K Kondo WY Kim M Lechpammer WG Kaelin 2003 Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 83 10.1371/journal.pbio.0000083 (Pubitemid 39112142)
19. WK Han V Bailly R Abichandani R Thadhani JV Bonventre 2002 Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury Kidney Int 62 237 244 12081583 10.1046/j.1523-1755.2002.00433.x 1:CAS:528:DC%2BD38XlsFyqurc%3D (Pubitemid 34754067)
20. MR Emmert-Buck JW Gillespie CP Paweletz, et al. 2000 An approach to proteomic analysis of human tumors Mol Carcinog 27 158 165 10708477 10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2 1:CAS:528:DC%2BD3cXhslKls7Y%3D (Pubitemid 30149311)
21. MH Sherief SH Low M Miura N Kudo AC Novick T Weimbs 2003 Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay J Urol 169 1530 1534 12629409 10.1097/01.ju.0000049201.91150.9d 1:CAS:528:DC%2BD3sXhvFahsLw%3D (Pubitemid 36323838)
22. HW Wechsel E Petri KH Bichler G Feil 1999 Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK) Anticancer Res 19 2583 2590 10470199 1:CAS:528:DyaK1MXlvVCmsbw%3D
23. N Yoshida S Ikemoto K Narita, et al. 2002 Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma Br J Cancer 86 1396 1400 11986770 10.1038/sj.bjc.6600257 1:CAS:528: DC%2BD38XkvVKjsLk%3D (Pubitemid 34548059)
24. P Mulders I Bleumer E Oosterwijk 2003 Tumor antigens and markers in renal cell carcinoma Urol Clin North Am 30 455 465 12953748 10.1016/S0094-0143(03) 00024-7 (Pubitemid 37069218)
25. A de la Taille Y Cao IS Sawczuk, et al. 2000 Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion Cancer Detect Prev 24 579 588 11198272
26. GM Oremek N Sapoutzis W Kramer R Bickeboller D Jonas 2000 Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma Anticancer Res 20 5095 5098 11326675 1:STN:280:DC%2BD3M3ovVSmsg%3D%3D